Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) missed Wall Street’s revenue expectations in Q4 CY2024, but ...
Q4 2024 Earnings Call Transcript February 18, 2025 NeoGenomics, Inc. beats earnings expectations. Reported EPS is $0.04, ...
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) will be reporting results tomorrow morning. Here’s what to ...
Hosted on MSN5d
Why NeoGenomics (NEO) Shares Are Trading Lower TodayWhat Happened? Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) fell 21.5% in the afternoon session ...
Strategic Financial Concepts LLC acquired a new stake in shares of NeoGenomics, Inc. (NASDAQ:NEO – Free Report) during the 4th quarter, according to its most recent filing with the SEC. The ...
NeoGenomics (NASDAQ:NEO – Get Free Report) had its target price reduced by Bank of America from $19.00 to $16.00 in a research note issued on Wednesday,Benzinga reports.The brokerage currently ...
NeoGenomics (NASDAQ:NEO – Get Free Report) had its price objective decreased by analysts at Needham & Company LLC from $19.00 to $18.00 in a report released on Wednesday,Benzinga reports.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback